Claims for Patent: 6,190,857

Summary for Patent: 6,190,857

Title:	Diagnosis of disease state using MRNA profiles in peripheral leukocytes
Abstract:	Disclosed are diagnostic techniques for the detection of human disease states that affect gene expression in peripheral leukocytes. The invention relates particularly to probes and methods for evaluating the presence of RNA species that are differentially expressed in the peripheral blood of individuals with such a disease state compared to normal healthy individuals. The invention further relates to methods for detection of protein species that are differentially expressed in the peripheral blood of individuals with such a disease state compared to normal healthy individuals. Genetic probes, antibody probes and methods useful in monitoring the progression and diagnosis of two specific disease states, prostatic cancer and breast cancer, are described.
Inventor(s):	Ralph; David (Edmond, OK), An; Gang (Oklahoma City, OK), O\'Hara; S. Mark (Oklahoma City, OK), Veltri; Robert (Oklahoma City, OK)
Assignee:	Urocor, Inc. (Oklahoma City, OK)
Application Number:	09/046,894
Patent Claims:	1. A method of detecting prostate cancer in a biological sample, comprising: (a) measuring the levels of IL-8 or IL-10 in combination with at least one prostate disease marker in said sample; and (b) comparing said levels with corresponding levels obtained from reference populations of normal individuals, individuals with BPH and individuals with prostate cancer. 2. The method of claim 1 in which said prostate disease marker is selected from a group consisting of total prostate specific antigen (PSA); prostate specific membrane antigen (PSMA=Folic Acid Hydrolase); prostate acid phosphatase (PAP); prostatic secretory proteins (PSP.sub.94); human kallekrein 2 (HK2); and the ratio of the concentrations of free and bound forms of PSA (f/t PSA). 3. The method of claim 2, in which the biological sample comprises peripheral human blood. 4. The method of claim 3, wherein the level of IL-8 in a biological sample is measured using at least one antibody that binds to an IL-8 gene product. 5. The method of claim 4, wherein the level of IL-8 gene product bound to antibody is measured by ELISA. 6. The method of claim 3, wherein the level of IL-8 in a biological sample is measured using at least one oligonucleotide probe that binds to an IL-8 messenger RNA (mRNA). 7. The method of claim 6, wherein an IL-8 mRNA is alternatively spliced to include intron 3. 8. The method of claim 6, wherein the level of oligonucleotide probe bound to IL-8 mRNA is measured by nuclease protection assay. 9. The method of claim 6, wherein the level of oligonucleotide probe bound to IL-8 mRNA is measured by RT-PCR.TM.. 10. The method of claim 6, wherein the level of oligonucleotide probe bound to IL-8 mRNA is measured by ligase chain reaction. 11. The method of claim 6, wherein the level of oligonucleotide probe bound to IL-8 mRNA is measured by PCR.TM.. 12. The method of claim 3, wherein the level of IL-8 in a biological sample is measured using an in vitro bioassay that detects an IL-8 mediated biological process. 13. The method of claim 3, wherein the level of IL-8 in a biological sample is measured using at least one molecule that binds to an IL-8 gene product, wherein said molecule is selected from a group consisting of: an IL-8 binding protein; and an IL-8 receptor protein. 14. The method of claim 2, wherein the level of prostate disease marker in a biological sample is measured using at least one antibody that binds to at least one prostate disease marker protein. 15. The method of claim 14, wherein the level of prostate disease marker protein bound to antibody is measured by ELISA. 16. The method of claim 2, wherein the level of prostate disease marker in a biological sample is measured using at least one oligonucleotide probe that binds to at least one prostate disease marker messenger RNA (mRNA). 17. The method of claim 6, wherein the level of oligonucleotide probe bound to prostate disease marker mRNA is measured by nuclease protection assay. 18. The method of claim 6, wherein the level of oligonucleotide probe bound to prostate disease marker mRNA is measured by RT-PCR.TM.. 19. The method of claim 6, wherein the level of oligonucleotide probe bound to prostate disease marker mRNA is measured by ligase chain reaction. 20. The method of claim 6, wherein the level of oligonucleotide probe bound to prostate disease marker mRNA is measured by PCR.TM.. 21. A method of differentially diagnosing prostate cancer and benign prostatic hyperplasia comprising the step of measuring the levels of IL-8 or IL-10 in combination with at least one prostate disease marker in a biological sample. 22. The method of claim 21 in which said prostate disease marker is selected from a group consisting of: total prostate specific antigen (PSA), prostate specific membrane antigen (PSMA=Folic Acid Hydrolase), prostate acid phosphatase (PAP), prostatic secretory proteins (PSP.sub.94), human kallekrein 2 (HK2), and the ratio of the concentrations of free and bound forms of PSA (f/t PSA). 23. The method of claim 21, in which said biological sample consists of peripheral human blood. 24. The method of claim 3, wherein the level of IL-10 in a biological sample is measured using at least one antibody that binds to an IL-10 gene product. 25. The method of claim 24, wherein the level of IL-10 gene product bound to antibody is measured by ELISA. 26. The method of claim 3, wherein the level of IL-10 in a biological sample is measured using at least one oligonucleotide probe that binds an IL-10 messenger RNA (mRNA).

Details for Patent 6,190,857

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2017-12-05
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2017-12-05
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2017-12-05